Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Survival of lung adenocarcinoma patients with malignant pleural effusion

Wu, S., Yu, C., Tsai, M., Liao, W., Yang, C.-H., Jan, I., Yang, P., & Shih, J. (2012) · European Respiratory Journal · doi:10.1183/09031936.00069812 · Cited by 96

Simulating non-small cell lung cancer with a multiscale agent-based model

Wang, Z., Zhang, L., Sagotsky, J., & Deisboeck, T. S. (2007) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-4-50 · Cited by 97

Evaluation of a biosensor-based graphene oxide-DNA nanohybrid for lung cancer

Kadhim, M. M., Rheima, A. M., Abbas, Z. S., Jlood, H. H., Hachim, S. K., Kadhum, W. R., & Kianfar, E. (2023) · RSC Advances · doi:10.1039/d2ra05808a · Cited by 94

YAP Promotes Malignant Progression of Lkb1 -Deficient Lung Adenocarcinoma through Downstream Regulation of Survivin

Zhang, W., Gao, Y., Li, F., Tong, X., Ren, Y., Han, X., Yao, S., Long, F., Yang, Z., Fan, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3396 · Cited by 96

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

König, K., Peifer, M., Fassunke, J., Ihle, M. A., Künstlinger, H., Heydt, C., Stamm, K., Ueckeroth, F., Vollbrecht, C., Bos, M. C. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000570 · Cited by 94

Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer

Valley, C. C., Arndt‐Jovin, D. J., Karedla, N., Steinkamp, M. P., Chizhik, A. I., Hlavacek, W. S., Wilson, B. S., Lidke, K. A., & Lidke, D. S. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-05-0269 · Cited by 93

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

Canale, M., Andrikou, K., Priano, I., Cravero, P., Pasini, L., Urbini, M., Delmonte, A., Crinò, L., Bronte, G., & Ulivi, P. (2022) · Cancers · doi:10.3390/cancers14051143 · Cited by 97

Receptor tyrosine kinases: biological functions and anticancer targeted therapy

Zhang, N., & Li, Y. (2023) · MedComm · doi:10.1002/mco2.446 · Cited by 97

Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src

Chung, B. M., Raja, S. M., Clubb, R. J., Tu, C., George, M., Band, V., & Band, H. (2009) · BMC Cell Biology · doi:10.1186/1471-2121-10-84 · Cited by 89

EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer

Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92

Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas

Looyenga, B. D., Furge, K. A., Dykema, K. J., Koeman, J. M., Swiatek, P. J., Giordano, T. J., West, A. B., Resau, J. H., Teh, B. T., & MacKeigan, J. P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012500108 · Cited by 99

Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

Caicedo, C., García‐Velloso, M. J., Lozano, M. D., Labiano, T., Díaz, C. V., López-Picazo, J. M., Gúrpide, A., Zulueta, J. J., Richter, J. Á., & Perez‐Gracia, J. L. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2833-4 · Cited by 93

Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung

Takahashi, R., Hirata, H., Tachibana, I., Shimosegawa, E., Inoue, A., Nagatomo, I., Takeda, Y., Kida, H., Goya, S., Kijima, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0868 · Cited by 91

CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses

Mei, D., Luo, Y., Wang, Y., & Gong, J. (2018) · Cancer Imaging · doi:10.1186/s40644-018-0184-2 · Cited by 91

A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue

Shi, Y., Huang, W., Tan, Y., Jin, X., Dua, R., Penuel, E. M., Mukherjee, A., Sperinde, J., Pannu, H., Chenna, A., et al. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31818cbdb2 · Cited by 91

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

Agarwal, S., Zerillo, C. A., Kolmakova, J., Christensen, J. G., Harris, L. N., Rimm, D. L., DiGiovanna, M. P., & Stern, D. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604937 · Cited by 92

Increased Prevalence of EGFR -Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms

Bell, D. W., Brannigan, B. W., Matsuo, K., Finkelstein, D. M., Sordella, R., Settleman, J., Mitsudomi, T., & Haber, D. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5030 · Cited by 91

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib

Callegari, D., Ranaghan, K. E., Woods, C. J., Minari, R., Tiseo, M., Mor, M., Mulholland, A. J., & Lodola, A. (2018) · Chemical Science · doi:10.1039/c7sc04761d · Cited by 92

Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

Lee, H.-J., Schaefer, G., Heffron, T. P., Shao, L., Ye, X., Sideris, S., Malek, S., Chan, E., Merchant, M., La, H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0357 · Cited by 90

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

Giaccone, G., & Wang, Y. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.01.003 · Cited by 94

Cucurbitacin B inhibits TGF-β1-induced epithelial–mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways

Yuan, R., Fan, Q., Liang, X., Han, S., He, J., Wang, Q.-Q., Gao, H., Feng, Y., & Yang, S. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00581-z · Cited by 90

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

Pallis, A. G., Voutsina, A., Kalikaki, A., Souglakos, J., Briasoulis, E. C., Murray, S. J., Koutsopoulos, A. V., Tripaki, M., Stathopoulos, E. N., Mavroudis, D., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604068 · Cited by 90

Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis

Smith, G. D., Chadwick, B. E., Willmore‐Payne, C., & Bentz, J. S. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.051425 · Cited by 90

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells

Zhu, Y., He, W., Gao, X., Li, B., Mei, C., Xu, R., & Chen, H. (2015) · Scientific Reports · doi:10.1038/srep17730 · Cited by 91

ICRP Publication 131: Stem Cell Biology with Respect to Carcinogenesis Aspects of Radiological Protection

Niwa, O., Barcellos‐Hoff, M. H., Globus, R. K., Harrison, J. D., Hendry, J. H., Jacob, P., Martin, M. T., Seed, T. M., Shay, J. W., Story, M. D., et al. (2015) · Annals of the ICRP · doi:10.1177/0146645315595585 · Cited by 91

Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer

Engel, J., Lategahn, J., & Rauh, D. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00475 · Cited by 90

Fucoidan inhibition of lung cancer in vivo and in vitro: role of the Smurf2-dependent ubiquitin proteasome pathway in TGFβ receptor degradation

Hsu, H.-Y., Lin, T., Wu, Y., Tsao, S.-M., Hwang, P., Shih, Y.-W., & Hsu, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2317 · Cited by 89

In situ cancer diagnosis through online plasmonics

Loyez, M., Larrieu, J.-C., Chevineau, S., Remmelink, M., Leduc, D., Bondue, B., Lambert, P., Deviere, J. M. E., Wattiez, R., & Caucheteur, C. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.01.062 · Cited by 89

Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics

Stella, G. M., Luisetti, M., Pozzi, E., & Comoglio, P. M. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70009-2 · Cited by 90

Advances in Treatment of Lung Cancer With Targeted Therapy

Cagle, P. T., & Chirieac, L. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0618-ra · Cited by 89

Mechanisms of acquired resistance to tyrosine kinase inhibitors

Chen, Y., & Fu, L. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.10.007 · Cited by 89

Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?

Bauml, J. M., Mick, R., Zhang, Y., Watt, C. D., Vachani, A., Aggarwal, C., Evans, T. L., & Langer, C. J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.011 · Cited by 91

Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells

Aljakouch, K., Lechtonen, T., Yosef, H. K., Hammoud, M. K., Alsaidi, W., Kötting, C., Mügge, C., Kourist, R., El‐Mashtoly, S. F., & Gerwert, K. B. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201803394 · Cited by 89

Potential clinical implications ofBRAFmutations in histiocytic proliferations

Bubolz, A.-M., Weissinger, S. E., Stenzinger, A., Arndt, A., Steinestel, K., Brüderlein, S., Cario, H., Lubatschofski, A., Welke, C., Anagnostopoulos, I., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2061 · Cited by 88

Drug Resistance to EGFR Inhibitors in Lung Cancer

Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W., & McCormick, F. P. (2016) · Chemotherapy · doi:10.1159/000443368 · Cited by 88

Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations

Avizienyte, E., Ward, R. A., & Garner, A. P. (2008) · Biochemical Journal · doi:10.1042/bj20080728 · Cited by 88

Sortilin limits EGFR signaling by promoting its internalization in lung cancer

Al‐Akhrass, H., Naves, T., Vincent, F., Magnaudeix, A., Durand, K., Bertin, F., Melloni, B., Jauberteau, M., & Lalloué, F. (2017) · Nature Communications · doi:10.1038/s41467-017-01172-5 · Cited by 94

Tumour molecular profiling for deciding therapy—the French initiative

Nowak, F., Soria, J., & Calvo, F. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.42 · Cited by 87

High‐Performance Nucleic Acid Sensors for Liquid Biopsy Applications

Das, J., & Kelley, S. O. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905005 · Cited by 87

Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family

Artim, S. C., Mendrola, J. M., & Lemmon, M. A. (2012) · Biochemical Journal · doi:10.1042/bj20121365 · Cited by 87

Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops

Gazdar, A. F., & Minna, J. D. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0080 · Cited by 88

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

Sun, W., Yuan, X., Tian, Y., Wu, H. K., Xu, H., Hu, G., & Wu, K. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0193-6 · Cited by 86

The Possible Role of Helicobacter pylori in Gastric Cancer and Its Management

Alfarouk, K. O., Bashir, A. H. H., Aljarbou, A. N., Ramadan, A. M., Muddathir, A. K., Alhoufie, S. T. S., Hifny, A., Elhassan, G. O., Ibrahim, M. E., Alqahtani, S. S., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00075 · Cited by 90

The Application of Molecular Diagnostic Studies Interrogating EGFR and KRAS Mutations to Stained Cytologic Smears of Lung Carcinoma

Betz, B. L., Roh, M. H., Weigelin, H. C., Placido, J. B., Schmidt, L. A., Farmen, S., Arenberg, D. A., Kalemkerian, G. P., & Knoepp, S. M. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcp84tutqosuong · Cited by 85

EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC

Penzel, R., Sers, C., Chen, Y., Lehmann-Mühlenhoff, U., Merkelbach‐Bruse, S., Jung, A., Kirchner, T., Büttner, R., Kreipe, H. H., Petersen, I., et al. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-1000-y · Cited by 85

Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced Phenotypes

Abelin, J. G., Patel, J., Lu, X., Feeney, C. M., Fagbami, L., Creech, A. L., Hu, R., Lam, D., Davison, D., Pino, L. K., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058354 · Cited by 87

The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodes

Wang, H., Xu, Y., Ning, S., Yang, D., Li, Y., Du, Y.-J., Yang, F., Zhang, Y., Liang, N., Yao, W., et al. (2014) · Cell Research · doi:10.1038/cr.2014.99 · Cited by 87

Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs

Mink, S. R., Vashistha, S., Zhang, W., Hodge, A., Agus, D. B., & Jain, A. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0460 · Cited by 89

Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors

Shimizu, T., LoRusso, P. M., Papadopoulos, K. P., Patnaik, A., Beeram, M., Smith, L. S., Rasco, D. W., Mays, T. A., Chambers, G., Ma, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0570 · Cited by 85

Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6

Park, E., Kim, N., Ficarro, S. B., Zhang, Y., Lee, B. I., Cho, A., Kim, K., Park, A. K.-J., Park, W., Murray, B. A., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3074 · Cited by 85

Anti-HER agents in gastric cancer: from bench to bedside

Fornaro, L., Lucchesi, M., Caparello, C., Vasile, E., Caponi, S., Ginocchi, L., Masi, G., & Falcone, A. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.81 · Cited by 84

Personalized Sequencing and the Future of Medicine: Discovery, Diagnosis and Defeat of Disease

Esplin, E. D., Oei, L., & Snyder, M. P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.117 · Cited by 91

Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

Girnun, G. D., Chen, L., Silvaggi, J. M., Drapkin, R., Chirieac, L. R., Padera, R. F., Upadhyay, R., Vafai, S. B., Weissleder, R., Mahmood, U., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1128 · Cited by 86

Disease-associated glycans on cell surface proteins

Takahashi, M., Kizuka, Y., Ohtsubo, K., Gu, J., & Taniguchi, N. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.04.008 · Cited by 85

Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping

Juchum, M., Günther, M., Döring, E., Sievers‐Engler, A., Lämmerhofer, M., & Laufer, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00178 · Cited by 84

Fast and Sensitive Pretargeted Labeling of Cancer Cells through a Tetrazine/trans‐Cyclooctene Cycloaddition

Devaraj, N. K., Upadhyay, R., Haun, J. B., Hilderbrand, S. A., & Weissleder, R. (2009) · Angewandte Chemie · doi:10.1002/ange.200903233 · Cited by 83

TAK1-Mediated Serine/Threonine Phosphorylation of Epidermal Growth Factor Receptor via p38/Extracellular Signal-Regulated Kinase: NF-κB-Independent Survival Pathways in Tumor Necrosis Factor Alpha Signaling

Nishimura, M., Shin, M.-S., Singhirunnusorn, P., Suzuki, S., Kawanishi, M., Koizumi, K., Saiki, I., & Sakurai, H. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00375-09 · Cited by 83

MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents

Fan, W., Tang, Z., Yin, L., Morrison, B., Hafez-Khayyata, S., Fu, P., Huang, H., Bagai, R. K., Jiang, S., Kresak, A. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2668 · Cited by 83

Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation

Leung, E. L., Fan, X., Wong, M. P., Jiang, Z., Liu, Z., Yao, X., Lu, L., Zhou, Y., Yau, L.-F., Tin, V. P., et al. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6420 · Cited by 84

NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance

Chiu, C., Chang, Y.-W., Kuo, K.-T., Shen, Y.-S., Liu, C., Yu, Y., Cheng, C.-C., Lee, K., Chen, F., Hsu, M.-K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522612113 · Cited by 82

Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

Yeo, W.-L., Riely, G. J., Yeap, B. Y., Lau, M. W., Warner, J. L., Bodio, K., Huberman, M. S., Kris, M. G., Tenen, D. G., Pao, W. J., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181dd1386 · Cited by 82

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience

Khunger, A., Khunger, M., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618767611 · Cited by 85

Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFR L858R/T790M/C797S

Li, Q., Zhang, T., Li, S., Tong, L., Li, J., Su, Z., Fěng, F., Sun, D., Tong, Y., Wang, X., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00564 · Cited by 81

Molecular therapeutic targets in non-small cell lung cancer

Sankar, K. N., Gadgeel, S. M., & Qin, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1787156 · Cited by 85

Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications

Shaban, N., Kamashev, D., Emelianova, A., & Buzdin, A. A. (2023) · Cells · doi:10.3390/cells13010047 · Cited by 88

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma

Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 83

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

Lin, L., & Bivona, T. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817297 · Cited by 85

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

Rolfo, C. D., Giovannetti, E., Hong, D. S., Bivona, T. G., Raez, L. E., Bronte, G., Buffoni, L., Reguart, N., Santos, E. S., Germonpré, P. R., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.009 · Cited by 80

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

Monica, S. L., Galetti, M., Alfieri, R. R., Cavazzoni, A., Ardizzoni, A., Tiseo, M., Capelletti, M., Goldoni, M., Tagliaferri, S., Mutti, A., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.033 · Cited by 80

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

Chen, M. C., Chen, C. H., Wang, J.-C., Tsai, A.-C., Liou, J.-P., Pan, S.-L., & Teng, C.-M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.330 · Cited by 80

Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045

Zhao, P., Yao, M.-Y., Zhu, S., Chen, J., & Yun, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.154 · Cited by 80

Selective Raf inhibition in cancer therapy

Khazak, V., Astsaturov, I. A., Serebriiskii, I. G., & Golemis, E. A. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.12.1587 · Cited by 81

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

Meng, F., Wang, F., Wang, L., Wong, S. C. C., Cho, W. C. S., & Chan, L. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00197 · Cited by 79

Monodentately-coordinated bioactive moieties in multimodal half-sandwich organoruthenium anticancer agents

Steel, T. R., Walsh, F. P., Wieczorek, A., Hanif, M., & Hartinger, C. G. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213890 · Cited by 80

Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)

Hu, L., Fan, M., Shi, S., Song, X., Wang, F., He, H., & Qi, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113963 · Cited by 79

Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells

Capuani, F., Conte, A., Argenzio, E., Marchetti, L., Priami, C., Polo, S., Fiore, P. P. D., Sigismund, S., & Ciliberto, A. (2015) · Nature Communications · doi:10.1038/ncomms8999 · Cited by 79

Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs

Burris, H. A. (2009) · Oncogene · doi:10.1038/onc.2009.196 · Cited by 82

Loss of Connectivity in Cancer Co-Expression Networks

Anglani, R., Creanza, T. M., Liuzzi, V. C., Piepoli, A., Panza, A., Andriulli, A., & Ancona, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087075 · Cited by 79

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells

Chen, Y., Huang, W., Wei, Y.-L., Hsu, S.-C., Yuan, P., Lin, H. Y., Wistuba, I. I., Lee, J. J., Yen, C.-J., Su, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021428 · Cited by 79

Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model

Kao, H.-W., Lin, Y.-Y., Chen, C., Chi, K., Tien, D., Hsia, C.-C., Lin, M.-H., & Wang, H. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.002 · Cited by 79

Targeting cathepsin S induces tumor cell autophagy via the EGFR–ERK signaling pathway

Chen, K.-L., Chang, W. W., Cheung, C. H. A., Lin, C., Huang, C., Yang, Y., Kuo, C.-P., Kuo, C., Chang, Y.-H., Liu, K., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.015 · Cited by 79

HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer

Jackson, A. L., Zhou, B. R., & Kim, W. Y. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.511617 · Cited by 82

Regulators of homologous recombination repair as novel targets for cancer treatment

Krajewska, M., Fehrmann, R. S. N., de Vries, E. G. E., & van Vugt, M. A. T. M. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00096 · Cited by 81

Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: A beneficial strategy to combat non-small cell lung cancer

Gorzalczany, Y., Gilad, Y., Amihai, D., Hammel, I., Sagi‐Eisenberg, R., & Merimsky, O. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.07.002 · Cited by 80

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

Chen, H., & Cheng, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66502 · Cited by 81

Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs

Chen, S., Zhao, J., Cui, L., & Liu, Y. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1534-9 · Cited by 79

Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR

Wassel, M. M. S., Ammar, Y. A., Ali, G. A. M. E., Belal, A., Mehany, A. B. M., & Ragab, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104794 · Cited by 78

Polygonatum odoratum lectin induces apoptosis and autophagy via targeting EGFR-mediated Ras-Raf-MEK-ERK pathway in human MCF-7 breast cancer cells

Ouyang, L., Chen, Y., Wang, X., Lu, R., Zhang, S., Tian, M., Xie, T., Liu, B., & He, G. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.08.002 · Cited by 78

Targeted therapies in the treatment of advanced/metastatic NSCLC

Pallis, A. G., Serfass, L., Dziadziuszko, R., van Meerbeeck, J. P., Fennell, D. A., Lacombe, D., Welch, J., & Gridelli, C. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.06.005 · Cited by 78

SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors

Milan, E., Lazzari, C., Anand, S. K., Floriani, I., Torri, V., Sorlini, C., Gregorc, V., & Bachi, A. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.06.022 · Cited by 78

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.

Jiang, T., & Zhou, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.08.02 · Cited by 77

Combinatorial Probes for High‐Throughput Electrochemical Analysis of Circulating Nucleic Acids in Clinical Samples

Das, J., Ivanov, I., Safaei, T. S., Sargent, E. H., & Kelley, S. O. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201800455 · Cited by 77

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

Lü, S., Zhou, J., Jian, H., Wu, L., Cheng, Y., Fan, Y., Fang, J., Chen, G., Zhang, Z., Lv, D., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00183-2 · Cited by 77

CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence

Chou, Y.-T., Hsieh, C.-H., Chiou, S.-H., Hsu, C.-F., Kao, Y.-R., Lee, C.-C., CHUNG, C. ‐., Wang, Y.-H., Hsu, H.-S., Pang, S.-T., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.91 · Cited by 77

Lung Tumor Suppressor GPRC5A Binds EGFR and Restrains Its Effector Signaling

Zhong, S., Yin, H., Liao, Y., Yao, F., Li, Q., Zhang, J., Jiao, H., Zhao, Y., Xu, D., Liu, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2005 · Cited by 77

Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment

Lee, D. H., Kim, S.-W., Suh, C. H., Yoon, D. H., Yi, E. J., & Lee, J.-S. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn423 · Cited by 77

Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern

Wu, S., Chang, Y., Hsu, Y.-C., Wu, J., Yang, C.-H., Yu, C., Tsai, M., Shih, J., & Yang, P. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0093 · Cited by 77

EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital

Choi, Y., Sun, J., Cho, J., Rampal, S., Han, J., Parasuraman, B. M., Güallar, E., Lee, G., Lee, J., & Shim, Y. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056011 · Cited by 79

Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth

Carnahan, J. F., Beltran, P. J., Babij, C., Le, Q., Rose, M. J., Vonderfecht, S. L., Kim, J. L., Smith, A. L., Nagapudi, K., Broome, M. A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0181 · Cited by 76

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156